Faculty Opinions recommendation of Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study.

Author(s):  
Hugh Barr
Gut ◽  
2014 ◽  
Vol 64 (1) ◽  
pp. 20-25 ◽  
Author(s):  
Shivaram K Bhat ◽  
Damian T McManus ◽  
Helen G Coleman ◽  
Brian T Johnston ◽  
Christopher R Cardwell ◽  
...  

2017 ◽  
Vol 117 (9) ◽  
pp. 1323-1331 ◽  
Author(s):  
Nitin Shivappa ◽  
James R. Hebert ◽  
Lesley A. Anderson ◽  
Martha J. Shrubsole ◽  
Liam J. Murray ◽  
...  

AbstractThe dietary inflammatory index (DIITM) is a novel composite score based on a range of nutrients and foods known to be associated with inflammation. DII scores have been linked to the risk of a number of cancers, including oesophageal squamous cell cancer and oesophageal adenocarcinoma (OAC). Given that OAC stems from acid reflux and that the oesophageal epithelium undergoes a metaplasia-dysplasia transition from the resulting inflammation, it is plausible that a high DII score (indicating a pro-inflammatory diet) may exacerbate risk of OAC and its precursor conditions. The aim of this analytical study was to explore the association between energy-adjusted dietary inflammatory index (E-DIITM) in relation to risk of reflux oesophagitis, Barrett’s oesophagus and OAC. Between 2002 and 2005, reflux oesophagitis (n219), Barrett’s oesophagus (n220) and OAC (n224) patients, and population-based controls (n256), were recruited to the Factors influencing the Barrett’s Adenocarcinoma Relationship study in Northern Ireland and the Republic of Ireland. E-DII scores were derived from a 101-item FFQ. Unconditional logistic regression analysis was applied to determine odds of oesophageal lesions according to E-DII intakes, adjusting for potential confounders. High E-DII scores were associated with borderline increase in odds of reflux oesophagitis (OR 1·87; 95 % CI 0·93, 3·73), and significantly increased odds of Barrett’s oesophagus (OR 2·05; 95 % CI 1·22, 3·47), and OAC (OR 2·29; 95 % CI 1·32, 3·96), when comparing the highest with the lowest tertiles of E-DII scores. In conclusion, a pro-inflammatory diet may exacerbate the risk of the inflammation-metaplasia-adenocarcinoma pathway in oesophageal carcinogenesis.


2001 ◽  
Vol 120 (5) ◽  
pp. A414-A415
Author(s):  
Liam J. Murray ◽  
R G Peter Watson ◽  
Brian T. Johnston ◽  
James A. McGuigan ◽  
James M. Sloan ◽  
...  

Endoscopy ◽  
2006 ◽  
Vol 38 (11) ◽  
Author(s):  
SJ Murphy ◽  
LA Anderson ◽  
RG Peter Watson ◽  
BT Johnston ◽  
H Comber ◽  
...  

2010 ◽  
Vol 38 (2) ◽  
pp. 343-347 ◽  
Author(s):  
Qizhi Huang ◽  
Laura J. Hardie

Biomarkers are needed to screen multiple stages in the clinical pathway of Barrett's oesophagus patients; from disease diagnosis to risk stratification and predicting response to therapy. Routes to the identification of biomarkers have been recognized by known molecular features of the disease and more recently through transcriptomic, methylation and proteomic screening approaches. The majority of Barrett's oesophagus patients remain undiagnosed in the general population. In order to develop a tool to screen for Barrett's oesophagus in the primary care setting, minimally invasive sampling methods coupled with immunocytology-based biomarkers are currently being assessed. Biomarkers may also have utility in surveillance programmes by allowing endoscopic interval to be adjusted according to individual neoplastic risk. Many individual biomarkers have been proposed in this regard, but have frequently been assessed in studies of limited power, or have lacked sufficient sensitivity or specificity when assessed in wider population-based studies. Biomarker panels may provide a route forward. In this regard, a panel of methylation markers has shown promise in a multicentre, double-blind, validation study. Biomarkers are also being developed to improve detection of high-grade dysplasia and oesophageal adenocarcinoma, utilizing brush cytology combined with FISH (fluorescence in situ hybridization), and to assess therapeutic success and risk of complication during photodynamic therapy. Finally, we outline progress in identifying alternative sources of biomarkers for this condition.


2009 ◽  
Vol 54 (7) ◽  
pp. 814-819 ◽  
Author(s):  
Piers Gatenby ◽  
James Ramus ◽  
Christine Caygill ◽  
Neil Shepherd ◽  
Marc Winslet ◽  
...  

2011 ◽  
Vol 65 (Suppl 1) ◽  
pp. A232-A232
Author(s):  
H. Coleman ◽  
S. Bhat ◽  
L. Murray ◽  
D. McManus ◽  
A. Gavin ◽  
...  

2001 ◽  
Vol 120 (5) ◽  
pp. A414-A415
Author(s):  
L MURRAY ◽  
R WATSON ◽  
B JOHNSTON ◽  
J MCGUIGAN ◽  
J SLOAN ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document